Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESD | P10768 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.46 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | AOC1 | P19801 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6298325 | 0.88 | ESD (0.60) | ESDMEN1KMT2AHSP90AA1ATM | |
| SCHEMBL6292699 | 0.87 | ESD (0.75) | ESDMEN1KMT2AHSP90AA1ATM | |
| SCHEMBL6294300 | 0.83 | ESD (0.63) | ESDMEN1KMT2AHSP90AA1ATM | |
| SCHEMBL6297386 | 0.82 | MAOB (0.49) | MEN1KMT2AHSP90AA1ATMMAOA | |
| SCHEMBL6294124 | 0.80 | ESD (0.52) | ESDMEN1KMT2AHSP90AA1ATM | |
| SCHEMBL6298319 | 0.80 | PDE5A (0.65) | ESDMEN1KMT2AHSP90AA1ATM | |
| SCHEMBL6292980 | 0.78 | MEN1 (0.45) | MEN1KMT2AHSP90AA1ATMPRKCZ | |
| SCHEMBL27997401 | 0.74 | ESD (1.00) | ESDMEN1KMT2AHSP90AA1ATM | |
| SCHEMBL6294120 | 0.74 | MEN1 (0.42) | MEN1KMT2AHSP90AA1ATMPRKCZ | |
| SCHEMBL7127148 | 0.71 | ESD (0.49) | ESDMEN1KMT2AHSP90AA1PRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030083351-A1 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY | 2003-05-01 | — | — | US | claimed |
| WO-2002089799-A2 | USE OF DIHYDROPYRAZOLES TO INCREASE ERYTHROPOIETIN AND VASCULARI ZATION | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-14 | — | — | WO | claimed |
| US-20050090532-A1 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY | 2005-04-28 | — | — | US | disclosed |
| US-6878729-B2 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20030083351-A1 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY | 2003-05-01 | — | — | US | disclosed |
| WO-2002089799-A2 | USE OF DIHYDROPYRAZOLES TO INCREASE ERYTHROPOIETIN AND VASCULARI ZATION | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090532-A1 | Medicinal uses of dihydropyrazoles | EPOR, VEGFA, FLT4 | ESD 2222/4885MEN1 3356/4885KMT2A 4588/4885 |
| US-20030083351-A1 | Medicinal uses of dihydropyrazoles | EPOR, VEGFA, TEK | ESD 2918/4885MEN1 3141/4885KMT2A 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.